BCI
KRYS icon

Brinker Capital Investments’s Krystal Biotech KRYS Stock Holding History

Brinker Capital Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Buy
887
+59
+7% +$17.6K ﹤0.01% 1602
2026
Q1 		$214K Sell
828
-99
-11% -$26.3K ﹤0.01% 1829
2025
Q4 		$228K Buy
+927
New +$195K ﹤0.01% 1951
2025
Q2 		– Sell
-1,160
Closed -$209K – 2026
2025
Q1 		$209K Buy
+1,160
New +$195K ﹤0.01% 1787
2024
Q4 		– Sell
-1,247
Closed -$227K – 1874
2024
Q3 		$227K Sell
1,247
-77
-6% -$14.8K ﹤0.01% 1657
2024
Q2 		$243K Sell
1,324
-148
-10% -$24.8K ﹤0.01% 1552
2024
Q1 		$262K Buy
+1,472
New +$204K ﹤0.01% 1510

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brinker Capital Investments's KRYS Position: Q2 2026 in Review

Brinker Capital Investments increased its Krystal Biotech (KRYS) stake by 7.1% in Q2 2026, buying an estimated $17.6K and bringing the position to 887 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #1602.

Brinker Capital Investments first reported a position in KRYS in Q1 2024 and has held it in 7 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Brinker Capital Investments held 887 shares of Krystal Biotech worth $330K as of Q2 2026.
  • Brinker Capital Investments bought 59 Krystal Biotech shares in Q2 2026, an estimated $17.6K.
  • Krystal Biotech made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1602 holding.
  • Brinker Capital Investments first reported a position in Krystal Biotech in Q1 2024 and has held it in 7 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.